Clinical Trials Logo

Clinical Trial Summary

Background:

Chemoradiation is an important treatment strategy of locally advanced inoperable or unresectable disease. Radiation dose is an independent predictor of a pathological response. In addition, chemotherapy has further impact on the aspect of outcome. Improvements in local treatment delivery are needed to facilitate dose escalation and to minimize toxicity. There have been sequential improvements in tumor localization, radiation planning and delivery over the years. Helical tomotherapy nowadays provides the most precise data on radiotherapy (RT) dose delivered to thoracic malignancies, and allows greater sparing of the heart from doses associated with increased complications. However, heart disease shows a wide spectrum of pathologies, and multiple risk factors related. The damage of the myocytes may lead to not only myocardial perfusion defects, but also in functional deterioration, or even in biomarkers.

Since the impact of radiation-induced heart injury in patients with thoracic malignancies (including esophageal cancer, lung cancer, et al) is poorly documented, we try to delineate of RT-related cardiac effects and clinical impacts.

Objective:

This study aims to investigate the correlation of post-tomotherapy cardiovascular effects with myocardial perfusion and cardiac functional studies.

Methods:

The study plans to enroll thoracic cancer patients who will undergo local RT after complete staging. Patients will receive global risk scoring assessment (Framingham Risk Score, FRS), blood sampling for basic biochemistry, inflammatory biomarker, and myocardial perfusion image (MPI) at the time points of before and after RT. The results of MPI will be analyzed in qualitative visual interpretation of perfusion patterns, and functional quantitative data for cardiac functional parameters as well. The patients will be regular followed-up in CV OPD, following clinical judgement and guideline. The association between baseline and follow-up MPI, biomarker and clinical presentation will be further investigated.

Expected results:

We will obtain myocardial perfusion visual qualitative data in patients who received locoregional RT, respectively. These results will help in the understanding of pathophysiology, clinical management and follow-up of suspected RT-related heart disease.


Clinical Trial Description

The risk of RT-related heart disease is now well recognized but the underlying mechanisms of its initiation and progression, and the roles played by microvascular damage, fibrosis and atherosclerosis remain unclear. Studying RT-related heart disease have demonstrated that irradiation affects cardiac structure and microvascular function in a dose and time-dependent manner, with substantial damage after intermediate and high dose irradiation, and minor alterations after lower doses. Not only structural changes but also functional deterioration was noted. Studies disclosing that incidence of post 3D-RT perfusion defect is in approximately 40%, and the patients had volume-dependent perfusion defects within 2 years of RT.

To better evaluation of the RT-related heart disease, we plan to initiate a prospective study trail that takes advantage of recent technical advances in tomotherapy, and new Cadimium-Zinc-Telluride (CZT) cardiac camera.

- Estimated Case Number: 100 patients will be enrolled in the study.

1. Patients with thoracic cancer will be transferred to CV OPD for initial cardiovascular risk factors assessment, before starting radiation therapy.

2. Past history, family history, basic lab data and Framingham cardiovascular risk assessment will be applied. After approaching risk stratification, patients who were classified as intermediated to high risk need further work-up. Who needs to undergo myocardial perfusion study will be enrolled in the study before further RT course.

3. All enrolled subjects provide basic demographic data and sign informed consents.

4. Myocardial perfusion images with Tl-201 and CZT camera will be performed in nuclear medicine department of FEMH, completing baseline evaluation before RT.

5. The patients received scheduled treatment plan, including RT.

6. Follow-up CV OPD based on clinical decision and guideline: blood biochemistry and inflammation marker, CV risk scores. Further work-up would be indicated if functional status deterioration or aggravated symptoms.

7. Post-therapeutic myocardial perfusion study 12 months after first CV OPD visit.

8. Comparing the clinical follow-up data between groups, including global functional assessments, blood sampling data, myocardial perfusion scan, and quantitative cardiac functional parameters.

Blood sampling Peripheral blood will be drawn for measurements of blood glucose, lipid profile, and circulating biomarker of CRP. The genomic tests will not be involved in the study.

Myocardial perfusion study-for quantitative functional parameters, qualitative and quantitative myocardial perfusion scan. Patients referred for SPECT MPI for evaluation of CAD underwent a 1-day Tl-201 stress/rest MPI protocol, as daily practice in FEMH. Pharmacological stress was induced by standard dipyridomale infusion. Tl-201 of 2 mCi was injected after 7 min of induced stress. The software package Myovation for Alcyone (GE Healthcare), QGS and QPS were used for quantitative analysis off MPI polar maps using a 17-segment model for the left ventricle. Automated analysis of gated acquisitions from high-dose (rest) scans was performed to determine left ventricular ejection fraction (LVEF).

Integrated clinical information, follow-up and nuclear medicine cardiac scans performed in the time points of before & after RT will be collected and analyzed. ;


Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01913769
Study type Observational
Source Far Eastern Memorial Hospital
Contact
Status Active, not recruiting
Phase N/A
Start date July 2013
Completion date July 2016

See also
  Status Clinical Trial Phase
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Completed NCT04741958 - Role of Ultrasound Guided Peripheral Thoracic Tumors N/A
Recruiting NCT04556344 - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer N/A
Terminated NCT03306693 - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers N/A
Completed NCT04751552 - Erector Spinae Block for Thoracoscopic Surgery N/A
Not yet recruiting NCT06104774 - The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery N/A
Completed NCT05770869 - mHealth ALIBIRD: A Digital Health Care Model N/A
Active, not recruiting NCT04589247 - Improving Cancer Symptom Management
Not yet recruiting NCT04133337 - Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC Phase 1/Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02188563 - A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers N/A
Completed NCT03134872 - A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC Phase 3
Not yet recruiting NCT04371796 - Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC Phase 2
Completed NCT00437372 - Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients Phase 1
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04862780 - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2
Recruiting NCT04776447 - Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) Phase 2
Recruiting NCT05988736 - Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients. N/A
Not yet recruiting NCT06376084 - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC